Medicine tariffs are pressing and demanding, AstraZeneca announces a $500 billion investment plan in the United States.

AstraZeneca announced on Monday that the company plans to invest $50 billion in expanding its production and research capabilities in the United States by 2030, making it the latest pharmaceutical giant to make a massive investment in response to Trump's tariff policies. AstraZeneca said in a statement that this investment will fund the construction of a new drug manufacturing facility in Virginia, as well as expanding research and cell therapy production in Maryland, Massachusetts, California, Indiana, and Texas. It will also upgrade its clinical trial supply network in the US and support ongoing investments in new drugs.